Alzheimer’s Disease Blood-Based Biomarkers Correlation With CSF AD Biomarkers

Overview

About this study

The purpose of this study is to evaluate the performance of various AD blood-based biomarkers including two pTau217 assays and an AB42/40 assay against the currently clinically available CSF AD biomarker assay (pTau181/AB42) for their ability to detect amyloid pathology in patients presenting with cognitive impairment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients undergoing a lumbar puncture procedure and testing for the Alzheimer’s Disease Evaluation test.

Exclusion Criteria:

Patients in whom the Alzheimer’s Disease Evaluation test was NOT order for clinical purposes.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Alicia Algeciras-Schimnich, Ph.D.	Open for enrollment	Contact information: Kimberly Massman (507) 266-0393 Massman.Kim@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Open for enrollment

Contact information:

Kimberly Massman

(507) 266-0393

Massman.Kim@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials